These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 309387)

  • 1. [Positive effects of L-dopa on a "marginal" symptomatology observed in parkinsonians].
    Morel-Maroger A
    Encephale; 1978; 4(3):223-31. PubMed ID: 309387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Parkinson syndrome, frontal tumor and L-dopa].
    Lhermitte F; Agid Y; Serdaru M; Guimaraes J
    Rev Neurol (Paris); 1984; 140(2):138-9. PubMed ID: 6710014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Trans-cerebral electrophoresis of L-DOPA in the complex treatment of parkinsonism].
    Neĭmark EZ; Evtushenko SK; Dukhovnaia MA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(9):1334-8. PubMed ID: 6506979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nosological concept of juvenile parkinsonism with reference to the dopa-responsive syndrome.
    Yokochi M
    Adv Neurol; 1993; 60():548-52. PubMed ID: 8420189
    [No Abstract]   [Full Text] [Related]  

  • 5. [The problem of side effects after a treatment with L-dopa in the Parkinson's syndrome: clinical and animal studies (author's transl)].
    Sommer H; Fischer GJ; Quandt J
    Folia Clin Int (Barc); 1974 Oct; 24(10):681-95. PubMed ID: 4279185
    [No Abstract]   [Full Text] [Related]  

  • 6. Vascular parkinsonism--an important cause of parkinsonism in older people.
    Thanvi B; Lo N; Robinson T
    Age Ageing; 2005 Mar; 34(2):114-9. PubMed ID: 15713855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Characteristics of regional cerebral circulation in parkinsonism patients according the 133Xe clearance findings].
    Man'kovskii NB; Vanishtok AB; Lizogub VG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1977; 77(1):51-5. PubMed ID: 842227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electroretinogram in parkinsonism and effects of L-DOPA.
    Filipová M; Terziivanov D; Balík J; Janků I; Filip V; Stika L; Krejcová H
    Act Nerv Super (Praha); 1981 Dec; 23(4):301-2. PubMed ID: 7336872
    [No Abstract]   [Full Text] [Related]  

  • 9. L-dopa resistant parkinsonism in an adult woman with a cyst in the posterior fossa.
    Ghika J; De Tribolet N; Regli F; Uské A
    Schweiz Arch Neurol Psychiatr (1985); 1993; 144(5):475-80. PubMed ID: 7504837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-dopa responsive parkinsonism secondary to a subdural haematoma.
    Ellul MA; Cross J; Barker RA
    J Clin Neurosci; 2013 Jul; 20(7):1022-4. PubMed ID: 23618681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term levodopa syndrome. Report of a clinical case].
    Bossi L; Nobili M
    Arch Sci Med (Torino); 1978; 135(4):637-9. PubMed ID: 756726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational analysis of open loop handwriting movements in Parkinson's disease: a rapid method to detect dopamimetic effects.
    Eichhorn TE; Gasser T; Mai N; Marquardt C; Arnold G; Schwarz J; Oertel WH
    Mov Disord; 1996 May; 11(3):289-97. PubMed ID: 8723147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical aspects and pathogenesis of the "on-off" phenomenon in Parkinson syndrome].
    Jörg J; Schneider I
    Fortschr Neurol Psychiatr; 1988 Jan; 56(1):22-34. PubMed ID: 3126121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experience with a l-dopa retard preparation in the peroral long-term therapy of the Parkinsonian syndrome].
    Binder H; Gerstenbrand F; Grünberger J; Gründig E; Schubert H
    Nervenarzt; 1976 Nov; 47(11):656-60. PubMed ID: 826840
    [No Abstract]   [Full Text] [Related]  

  • 15. [Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination].
    Boudin G; Pepin B; Guillard A; Godlewski S; Fabiani JM; Haguenau M
    Rev Neurol (Paris); 1974; 130(7-8):273-84. PubMed ID: 4217929
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical and biochemical considerations on depressive states occuring during parkinsonian syndrome treated by L-Dopa].
    Gisselmann A; Boudry C; Marin A; Ballivet J
    Encephale; 1976; 2(2):105-13. PubMed ID: 1278088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of a therapeutic failure of L-Dopa: can Adams-Van Bosaert and Van Der Eecken's strio-nigral degeneration be diagnosed during the patient's life?].
    André JM; Royer RJ; Duc M; Kissel P
    Rev Neurol (Paris); 1974; 130(7-8):322-6. PubMed ID: 4453761
    [No Abstract]   [Full Text] [Related]  

  • 18. Subthalamic nucleus stimulation modulates motor cortex oscillatory activity in Parkinson's disease.
    Devos D; Labyt E; Derambure P; Bourriez JL; Cassim F; Reyns N; Blond S; Guieu JD; Destée A; Defebvre L
    Brain; 2004 Feb; 127(Pt 2):408-19. PubMed ID: 14691060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The L-dopa sparing effect of G 31,406 in the treatment of parkinson's disease.
    Couto B; Oliveira C; Mattos JP; Freitas MR
    Neurol Neurocir Psiquiatr; 1976; 17(4):285-92. PubMed ID: 798128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.